What is Mibefradil?
Mibefradil was a medicine that was once approved for the treatment of angina and hypertension. The drug is no longer available due to evidence of serious drug interactions. The Global Health Society, Switzerland F. Hoffmann-La Roche Ltd., produced and launched the market under the name Posicor. This means that it passes through membrane channels in the body specifically designed for calcium- specifically for T- and L-channels of calcium- and slows the movement of this chemical element. This reduces the amount of calcium in blood vessels, which helps to relax and supply the heart more blood -rich blood. Angina follows her roots to the Greek word anonone , which means that strangulation and pectoris are related to the Latin word chest, pectus . Angina is considered a prelude infarction of myocardial or heart attack. Therefore, with more oxygen supplied to the heart muscles, the workload of the organs is significantly reduced.
people also used Mibefradil to treat hypertension, which is characterized by high blood pressure. Like Angina is hypertensionOne of the risk factors of heart attack. However, the drugs were used to control high blood pressure, not its cure.
During the production Roche, he usually produced and sold Mibefradil in 50 or 100-derishment tablets. The drug was designed for oral administration, with a recommended dose of 50 mg once daily. The most common side effects of Mibefradil were abdominal pain, dizziness, headache, fatigue, nasal overload, nausea and swelling of the legs. More serious grades that were rarely included breathing problems, fainting of magic, skin rashes and Slostarde -rytht.
In August 1997, the United States of Food & Drug Administration (FDA) MIbefradil approved. It has placed it in its middle pregnancy category C category of classification system for the level of drug damage represents pregnancy. Animal studies that included serving 39 mm Mibefradil have shown that the medicine is associated with a number of defects like JSOU prolonged pregnancy, difficult birth, dead births and skeletal abnormalities. Despite the above risks in some cases, the FDA pointed to the benefits of the drug as a predominant factor. Roche, however, on June 8, 1998 voluntarily pulled Mibefradil from the pharmaceutical market and quoted potentially dangerous drug interactions with 25 drugs.